Kodama T, Nishiyama H, Nishiwaki Y
Matsudo National Hospital.
Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Feb;28(2):216-24.
In 678 cases of surgically resected lung cancer, morphological factors influencing prognosis were evaluated, especially in adenocarcinomas (283 cases) and squamous cell carcinomas (270 cases). In adenocarcinoma cases, sex, degree of differentiation, classification by cell type, lymphatic invasion, vascular invasion, pleural involvement, intrapulmonary metastasis, grade of scarring associated with a tumor, atypia of cells and mitotic index were significantly evaluated. The scoring of these factors will contribute to the clinician's decisions on the necessity and selection of post-adjuvant chemotherapy, especially even in Stage I. In squamous cell carcinoma cases, location of tumor, tumor size, lymphatic invasion, vascular invasion and pleural involvement were also significantly evaluated. In 160 patients treated by chemotherapy involving cisplatin, chemotherapeutic response in squamous cell carcinoma (39 cases) was more effective and survived longer these than in adenocarcinoma (107 cases) and large cell carcinoma (14 cases). In 233 non-small cell lung cancer patients treated by chemotherapy, there were 33 cases of long-term survival more than 2 years; that is, 8 cases (3.4%) disease-free and 25 cases (10.7%) alive with cancer. The group which remained disease-free for over 2 years, consisted only of patients with Stage IIIa or IIIb, and PR was achieved with chemotherapy and radiation. Among patients who lived over 2 years, many squamous cell carcinoma cases (5/6) remained disease-free. On the other hand, adenocarcinoma was less responsive to chemotherapy and almost all cases (24/27) were alive with cancer. The relationship between the effectiveness of chemotherapy and prognosis among histological subtypes was examined in small cell lung cancer.(ABSTRACT TRUNCATED AT 250 WORDS)
在678例接受手术切除的肺癌患者中,评估了影响预后的形态学因素,尤其针对腺癌(283例)和鳞状细胞癌(270例)。在腺癌病例中,对性别、分化程度、细胞类型分类、淋巴浸润、血管浸润、胸膜受累、肺内转移、肿瘤相关瘢痕分级、细胞异型性和有丝分裂指数进行了显著评估。这些因素的评分将有助于临床医生决定辅助化疗的必要性和选择,尤其是在I期患者中。在鳞状细胞癌病例中,还对肿瘤位置、肿瘤大小、淋巴浸润、血管浸润和胸膜受累进行了显著评估。在160例接受含顺铂化疗的患者中,鳞状细胞癌(39例)的化疗反应比腺癌(107例)和大细胞癌(14例)更有效,生存期更长。在233例接受化疗的非小细胞肺癌患者中,有33例长期生存超过2年;即8例(3.4%)无病生存,25例(10.7%)带癌生存。无病生存超过2年的组仅由IIIa期或IIIb期患者组成,通过化疗和放疗实现了部分缓解。在生存超过2年的患者中,许多鳞状细胞癌病例(5/6)保持无病状态。另一方面,腺癌对化疗反应较差,几乎所有病例(24/27)带癌生存。在小细胞肺癌中研究了组织学亚型之间化疗疗效与预后的关系。(摘要截短至250字)